Heart health marker
This article was originally published in The Gray Sheet
Executive Summary
C-reactive protein is a stronger predictor of cardiovascular events than low-density lipoprotein (LDL) cholesterol, according to a study led by Paul Ridker, MD, Brigham and Women's Hospital in Boston, reported in the Nov. 14 issue of the New England Journal of Medicine. The study followed 27,939 apparently healthy American women for eight years, correlating LDL cholesterol and C-reactive protein levels to incidence of myocardial infarction, ischemic stroke, coronary revascularization and cardiovascular-related death...
You may also be interested in...
CRP test endorsed
American Heart Association and CDC recommend high-sensitivity C-reactive protein testing as an option to facilitate heart disease risk assessment and potential treatment selection when other factors project a 10-year CHD risk of 10%-20%. Published in the Jan. 28 issue of Circulation, guidelines suggest additional studies of the systemic inflammation marker test are needed to clarify appropriate use. A recent 28,000-patient study by Paul Ridker, MD, Brigham and Women's Hospital, Boston, et al., showed the roughly $20 CRP test is a stronger predictor of cardiovascular events than LDL cholesterol ("The Gray Sheet" Nov. 18, 2002, In Brief). CRP test product makers include Bayer, Beckman Coulter, Dade Behring and Diagnostic Products...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.